IONS
Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals Inc historical holders
total: 1
Tweedy, Browne Co All Funds (US) Ionis Pharmaceuticals Inc transactions over time
- Total transactions:
- 14
- New positions:
- 1
- Added:
- 2
- Reduced:
- 11
- Held since:
- 2022 Q1
- Held for:
- 17 quarters
- Latest activity:
- 2026 Q1
Tweedy, Browne Co All Funds (US) has been an institutional investor in Ionis Pharmaceuticals Inc (IONS) since 2022 Q1. According to 2026 Q1 report, Tweedy, Browne Co All Funds (US) holds 2,275,625 shares with a market value of roughly $170.88M representing 13.57% of their equity portfolio. The fund/company first acquired IONS in 2022 Q1, initially purchasing about 2.93M shares. Since the initial investment, Tweedy, Browne Co All Funds (US) has made 13 more transactions in this position.
Does Tweedy, Browne Co All Funds (US) still hold IONS?
Yes, Tweedy, Browne Co All Funds (US) continues to hold Ionis Pharmaceuticals Inc (IONS). According to their 2026 Q1 report, they maintain a position of 2,275,625 shares valued at approximately $170.88M, representing 13.57% of their equity portfolio.
When did Tweedy, Browne Co All Funds (US) first invest in IONS?
Tweedy, Browne Co All Funds (US) first invested in Ionis Pharmaceuticals Inc (IONS) in 2022 Q1 at the reported quarter-end price of $37.04 per share, acquiring 2,925,102 shares in their initial purchase.
What is Tweedy, Browne Co All Funds (US)'s average cost basis for IONS?
Based on historical transaction data, Tweedy, Browne Co All Funds (US)'s estimated cost basis for Ionis Pharmaceuticals Inc (IONS) is approximately $37.27 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $37.27
- Weighted AVG sell price:
- $53.67
IONS transactions history by Tweedy, Browne Co All Funds (US)
14 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
13.57%
|
2,275,625
|
$75.09
|
$170,876,681
|
-7.68% (-189,305)
|
-1.15%
|
|
2025 Q4
|
15.74%
|
2,464,930
|
$79.11
|
$195,000,612
|
-15.04% (-436,286)
|
-3%
|
|
2025 Q3
|
16.48%
|
2,901,216
|
$65.42
|
$189,797,551
|
+0.32% (+9,268)
|
+0.05%
|
|
2025 Q2
|
10.60%
|
2,891,948
|
$39.51
|
$114,260,865
|
-3.07% (-91,570)
|
-0.32%
|
|
2025 Q1
|
7.98%
|
2,983,518
|
$30.17
|
$90,012,738
|
-8.17% (-265,345)
|
-0.54%
|
|
2024 Q4
|
7.66%
|
3,248,863
|
$34.96
|
$113,580,250
|
-5.96% (-205,813)
|
-0.34%
|
|
2023 Q4
|
8.53%
|
3,454,676
|
$50.59
|
$174,772,059
|
-1.58% (-55,497)
|
-0.15%
|
|
2023 Q3
|
8.52%
|
3,510,173
|
$45.36
|
$159,221,447
|
-0.87% (-30,685)
|
-0.07%
|
|
2023 Q2
|
7.63%
|
3,540,858
|
$41.03
|
$145,281,000
|
-0.01% (-188)
|
-0%
|
|
2023 Q1
|
6.89%
|
3,541,046
|
$35.74
|
$126,557,000
|
-0.00% (-90)
|
-0%
|
|
2022 Q4
|
7.12%
|
$37.77
|
+30.05% (+818,148)
|
|||
|
2022 Q3
|
5.30%
|
$44.23
|
-0.14% (-3,790)
|
|||
|
2022 Q2
|
4.13%
|
$37.02
|
-6.78% (-198,324)
|
|||
|
2022 Q1
|
3.50%
|
$37.04
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.